Research of Biomarkers in Parkinson Disease

NCT00465790 | Completed

• 2 other identifiers: C06-562007-A00208-45
• Study Type: observational
• Target: 219
• Locations: 4 countries
• Sites: 5

Brief Summary

The main goal of the GENEPARK consortium is to employ innovative haemogenomic approaches to determine gene expression profiles specific for genetic and idiopathic Parkinson's disease (PD) patients. These gene expression signatures will be utilised clinically as non-invasive diagnostic tests for PD. The sensitivity of the newly developed diagnostic test will be determined by extensive validations on an independent cohort of PD patients, whereas the specificity will be assessed by testing patients with atypical parkinsonisms, including multiple system atrophy, progressive supranuclear palsy and diffuse Lewy body disease. In order to test the specificity of the diagnostic set in other disorders that affect basal ganglia, Huntington's disease and dopa responsive dystonia patients will be analysed. The second objective of the proposal is to determine correlations between gene expression signatures and different stages of PD and thus provide the basis for early diagnosis and monitoring of disease progression. These changes in blood gene expression will be correlated with alterations detected by neuroimaging in the brain of PD patients. Such combinations of molecular and morphological markers of disease may ultimately facilitate the selection and monitoring of neuroprotective therapies for PD. Finally, GENEPARK aims to develop new bioinformatic software tools for selection of genomic biomarkers using microarray data. A set of established computational tools will be applied and novel methods, some of them based on mechanistic modelling of the neurodegenerative diseases, will be developed in order to study the advantages and limitations of the different methodologies. With special emphasis on the careful clinical selection of patients and sufficient power regarding patient numbers, as well as extensive quality control and validation of the data, GENEPARK aims to develop a standardised approach to development and validation of haemogenomic biomarkers of disease.

Conditions

Parkinson Disease; Multiple System Atrophy; Progressive Supranuclear Palsy; Huntington Disease; Dystonia; Diffuse Lewy Body Disease

Keywords

biomarkers; neuroimaging; genetics; PET; Genetic and Idiopathic Parkinson; Multiple Systemic Atrophy; Huntington; Dopa Responsive Dystonia

Eligibility Criteria

• Age: 18 Years - 90 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with Parkinson's disease and related

You may qualify if:

• Diagnosis of Parkinson's disease
• Ability to understand the aim of the study
• Ability to sign the consent form

You may not qualify if:

• Non ability to understand the aim of the study
• Non ability to sign the consent form
• To be over 18

Sponsors & Collaborators

• Institut National de la Santé Et de la Recherche Médicale, France: lead
• European Union: collaborator

Study Sites (5)

Meditterranean Institute for Life Sciences

Split, Croatia

Location

INSERM Unit 679

Paris, 75013, France

Location

University of Lübeck and Neuroimage Nord

Lübeck, Germany

Location

University Hospital Tübingen

Tübingen, Germany

Location

University Medical Center Ljubljana

Ljubljana, 1000, Slovenia

Location

Related Links

• Related Info

MeSH Terms

Conditions

Parkinson Disease; Multiple System Atrophy; Supranuclear Palsy, Progressive; Huntington Disease; Dystonia; Lewy Body Disease; Dystonia, Dopa-responsive

Condition Hierarchy (Ancestors)

Parkinsonian Disorders; Basal Ganglia Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases; Primary Dysautonomias; Autonomic Nervous System Diseases; Ophthalmoplegia; Ocular Motility Disorders; Cranial Nerve Diseases; Tauopathies; Paralysis; Neurologic Manifestations; Eye Diseases; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Dementia; Chorea; Dyskinesias; Heredodegenerative Disorders, Nervous System; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Cognition Disorders; Neurocognitive Disorders; Mental Disorders

Study Officials

• Borut Perterlin, MD, PhD

  University Medical Centre Ljubljana

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Sponsor Type: OTHER GOV
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 23, 2007
• First Posted: April 25, 2007
• Study Start: October 1, 2007
• Primary Completion: June 1, 2012
• Study Completion: June 1, 2012
• Last Updated: September 27, 2012

Record last verified: 2011-12

Locations

CR (1); FR (1); DE (2); SL (1)